Comment on: Kim et al. Prospective Study of Serum Adiponectin and Incident Metabolic Syndrome: The ARIRANG Study. Diabetes Care 2013;36:1547–1553

Kim et al. (1) conducted a 2.6-year follow-up study targeting 5,178 inhabitants aged 40 to 70 years to elucidate the effect of serum adiponectin on the risk of development of metabolic syndrome (MetS). The number of participants in the first follow-up survey was 3,862, and the final sample size became 2,044 (831 men and 1,213 women), after exclusion of subjects for several reasons, including lack of adiponectin measurement and diagnosis of MetS in the baseline study. They calculated the odds ratio using multivariate logistic regression analysis. In addition, they checked the improvement of the predictive ability of serum adiponectin for MetS using a statistical procedure named receiver …